Stifel raised the firm’s price target on Crinetics (CRNX) to $84 from $75 and keeps a Buy rating on the shares. The Q4 pre-report surpassed early investor expectations for the first quarter of the Palsonify launch in Acromegaly, notes the analyst, whose analysis supports an increase in the firm’s 2026 Palsonify estimates.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics doses first patient in BALANCE-CAH trial
- ‘Markets Climb Wall-of-Worry’: Oppenheimer Sees Resilience Driving 2026 and Suggests 2 Stocks to Buy
- Crinetics Highlights Breakout Year and Strong Endocrinology Pipeline
- Crinetics Pharmaceuticals: Phase 2 TouCAHn De‑Risking and Optimized Phase 3 Design Drive Upgrade to Buy and $67 Target
- Crinetics upgraded to Buy from Neutral at Goldman Sachs